Other dietary exposures: There was a protective effect between menaquinone intake and prostate cancer: HR 0.37 (0.16–0.88) for advanced prostate cancer [118], HR 0.65 (0.44–0.97) for prostate cancer incidence [108], OR 1.38 (1.03–1.86) for serum undercarboxylated osteocalcin (ucOC)/intact osteocalcin (iOC) ratio in advanced-stage prostate cancer [119], and OR 1.21 (1.00–1.46) for serum ucOC/iOC ratio in high-grade prostate cancer [119]. Here, BGLAP is linked to prostate cancer.